U.S. markets closed
  • S&P Futures

    3,408.25
    -24.25 (-0.71%)
     
  • Dow Futures

    27,939.00
    -195.00 (-0.69%)
     
  • Nasdaq Futures

    11,617.25
    -74.00 (-0.63%)
     
  • Russell 2000 Futures

    1,592.50
    -10.60 (-0.66%)
     
  • Crude Oil

    39.78
    -0.25 (-0.62%)
     
  • Gold

    1,916.00
    -13.50 (-0.70%)
     
  • Silver

    24.90
    -0.35 (-1.37%)
     
  • EUR/USD

    1.1846
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    0.8160
    +0.0190 (+2.38%)
     
  • Vix

    28.65
    -0.70 (-2.39%)
     
  • GBP/USD

    1.3126
    -0.0017 (-0.13%)
     
  • USD/JPY

    104.7290
    +0.1690 (+0.16%)
     
  • BTC-USD

    12,765.81
    +1,708.80 (+15.45%)
     
  • CMC Crypto 200

    255.90
    +11.01 (+4.50%)
     
  • FTSE 100

    5,776.50
    -112.72 (-1.91%)
     
  • Nikkei 225

    23,454.85
    -184.61 (-0.78%)
     

Xeris Pharmaceuticals'(NASDAQ:XERS) Share Price Is Down 31% Over The Past Year.

Simply Wall St
·3 mins read

Over the last month the Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) has been much stronger than before, rebounding by 58%. But that doesn't change the fact that the returns over the last year have been less than pleasing. The cold reality is that the stock has dropped 31% in one year, under-performing the market.

See our latest analysis for Xeris Pharmaceuticals

Xeris Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last year Xeris Pharmaceuticals saw its revenue grow by 218%. That's well above most other pre-profit companies. Given the revenue growth, the share price drop of 31% seems quite harsh. Our sympathies to shareholders who are now underwater. On the bright side, if this company is moving profits in the right direction, top-line growth like that could be an opportunity. Our monkey brains haven't evolved to think exponentially, so humans do tend to underestimate companies that have exponential growth.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Xeris Pharmaceuticals stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

Given that the market gained 15% in the last year, Xeris Pharmaceuticals shareholders might be miffed that they lost 31%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Putting aside the last twelve months, it's good to see the share price has rebounded by 24%, in the last ninety days. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for Xeris Pharmaceuticals you should be aware of, and 1 of them makes us a bit uncomfortable.

Xeris Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.